Tharimmune Inc.


Randy Milby - CEO & Chairman

Mr. Milby was the former Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. A seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.

Sireesh Appajosyula, PharmD – Chief Operating Officer

Sireesh Appajosyula joined as COO in July of 2023 and has served as a member of our board of directors since July 2021. Previously, he was SVP, Corporate Development and Operations of 9 Meters Biopharma, a company focused on rare and unmet needs and is Managing Member of Highpoint Pharmaceuticals, LLC, a pharmaceutical research and development company. In addition, since 2015, Mr. Appajosyula has served as Managing Partner of Channel BioConsulting, LLC, a company that assists in enhancing search and evaluation efforts for complementary assets to be added to existing portfolios of biopharmaceutical companies. Prior to 9 Meters, Mr. Appajosyula was at Salix Pharmaceuticals, Inc. (“Salix”) (Nasdaq: SLXP) in various roles in medical affairs, product commercialization and business development until its acquisition by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in various roles at Amgen Inc., Critical Therapeutics, Inc. (now Chiesi) and Sanofi (formerly Aventis). Mr. Appajosyula received his Bachelor of Science and Doctor of Pharmacy from Rutgers University.

Thomas Hess CPA - Chief Financial Officer

Thomas Hess is an experienced financial expert. From August 2014 until June 2021, Mr. Hess served as Chief Financial Officer and Senior Vice President of Finance of Genomind, Inc., a mental health company that developed and sold a pharmacogenomic test that analyzed how an individual’s genes may affect medication outcomes. From September 2011 until its sale in April 2014, Mr. Hess served as Chief Financial Officer and Executive Vice President of Finance of The Keane Organization, a comprehensive provider of unclaimed property services. Mr. Hess also previously served in various other capacities including, but not limited to, Chief Financial Officer and Senior Vice President of Yaupon Therapeutics, Inc.; Chief Financial Officer and Vice President, Finance of Adolor Corporation; Corporate Controller of Vicuron Pharmaceuticals, Inc.; and Senior Manager – Accounting and Audit of KPMG. Mr. Hess was formerly an adjunct faculty member/lecturer at Pennsylvania State University and DeSales University. Mr. Hess received his B.S. in accounting from The Pennsylvania State University and his MBA from Katz Graduate School of Business, University of Pittsburgh. Mr. Hess is a Certified Public Accountant in the state of Pennsylvania. He currently serves on the Alumni Council of Penn State and is the Chairman of the Nittany Lion Club Annual Fund.

Nir Barak, MD - Chief Medical Advisor

Dr. Barak serves as the Chief Medical Advisor of Theraimmune since October 2023. Previously he served as the Chief scientific Officer of 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a company focused on rare and unmet needs in gastrointestinal patient populations developing compounds with unique gastrointestinal biology. In 2008, after 10 years of working as an attending in Internal Medicine in a major hospital, Dr Barak founded RDD Pharma, a company focused on repurposing of drugs for anorectal indications. Under his leadership, RDD Pharma raised an investment from Orbimed, and in 2019 the company was merged to form 9 Meters Biopharma. Dr Barak received his MD from Tel-Aviv University, is board certified in Internal Medicine and completed 2 years of post-doctoral fellowship in the University of Chicago Hospitals.